L~g cancer is the most frequent malignant disease in the male population, accounting for 37% of certified causes of death from all malignant diseases (M. Bates: Bronchial carcinoma, Springer Berlin 1984). There is still general agreement in the literature that surgical resection of all non small cell types still carries the best prognosis providing an overall five year survival rate of approx. 25%. Marked progress in surgery and anesthesiology has decreased operative mortality of lobectomy and pneur~nectomy from 15 -2(Y/~ down to 2-5 %. However it has been pointed out repeatedly that all propress in surgical techniques -has not been able to improve overall survival figures within the past 30 years: Longtem sucess of surgery is extremiy dependant upon TN~ staging: 5 year survival in TI NO tomors is reported up to 9(Y/o, whereas TX N2 tomors carry a poor prognosis with 5 years survival of approx. 13% (N. Martini 1982). In our own group of 464 patient, resected for lung cancer from 1979 to 1985 only 13% were TI tunors 'whereas in 64% the tomor had increased to T2 and in 23% to T3 stages. Infiltration of mediastinal lymphnodes (LN) which carries the worst prognosis was found in almost one fifth of all resections, perioperative mortality was 2% for lobectomy and pneu~onectomy. Hilar and mediastinal LN staging was carried out in every patient, radical mediastinal LN dissection performed whenever lymphnodes where found to be enlarged. In contrast to general beleave only 40% of enlarged LN (~ 2cm) were infiltrated by carcinoma whereas 6~ were enlarged by nonspecific l~ffnphadeniti s. From our experience we conclude that: I. Early diagnosis of bronchial cancer has to be improved, since late results of surgery are excellent in early bronchial cancer and operative mortality is low (e,~ 2 %). 2. Mediastinal lymphnode enlargement per se does not preclude curative resection. LN staging and radical dissection however is a must. The treatment of small cell lung cancer (SCLC) and of non small cell lung cancer (NSCLC) has failed to further improve survival rates during recent years indicating the need to study the biology of lung cancer in detail in order to establish new treatment modalities that are more specifically adapted to the properties of lung cancer. To accomplish this task, we have established 7 SCLC and 4 non-SCLC cell lines from body cavity effusions, bone marrow aspirates, and solid tumor lesions of lung cancer patients undergoing diagnostic or treatment procedures. All SCLC cell lines (designated SCLC-16H, -21H, -22H, -24B, -86MI, -86M2, -203H} grew as floating cell aggregates in serum-supplemented medium (RPMI 1640 + 10% FBS) and with equal growth rates in serum-free medium (RPMI + selenium, insulin, transferrin). Population doubling times ranged from 45-200 hr, and all cell lines formed colonies in soft agarose with an efficieny of 0.06-3.4 %. Nude mouse xenografts that developed with a latent period of 4-8 weeks after subcutaneous 6 inoculation of 2xlO cells showed typical small cell histology of the intermediate cell typet and in one instance a mixed small cell/large cell histology was found. Ultrastructural analysis revealed dense core granules in all SCLC cell lines. The levels of the neuroendocrine system markers L-dopa decarhoxylase, neuron-specific enolase, and the total creatine kinase activity as well as the level of its BB-isoenzyme clearly distinguished SCLC cell lines from non-SCLC cell lines (designated EPLC-32M4, EPLC-65M2, LCLC-I03B, MSTO-211H) with marker levels being elevated in SCLC cell lines only. Detectable levels of bombesin, the 14 amino acid amphibian peptide recently suggested to function as an autocrine growth factor in SCLC, were found by means of a polyclonal double antibody radioimmunoassay in 2/6 SCLC and 0/4 non-SCLC cell lines. Flow cytometric DNA analysis revealed near diploid indices in all SCLC cell lines and hyperploid indices in non-SCLC cell lines. These well characterized continuously growing lungcancer cell lines may provide an easy basis to further investigate the biology of lung cancer. Biol. Chem. 250, 4297, 1975; Parker et al., J. Biol. Chem. 259, 9906, 1984; Fitzpatrick et al., Cancer Res. 44, 3442, 1984). These results demonstrate the presence of saturable high affinity EGF binding sites on non-small cell lung cancer cell lines and a urinary bladder carcinoma cell line. To further characterize the EOF binding sites, immunohistochemistry and competition studies of EGF receptors with monoclenal antibodies are necessary~ in particular with respect to the possible growth regulation of cancer cells by EGF/EGF receptor interaction.
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Sole criterion for proof of BMI was the presence of tumor cells. The median surface area of the bone marrow sections examined per patient was 54 mm2.There was no difference between biopsies with and without BMI.7 of the 243 patients (3%) showed a BMI in the biopsy. These were exclusively cases with SCCL(7/80 =9%). 3/7 patients exhibited BMI only on one side. All 7 patients with BMI already had distant metastases, large primary tumors,and lymph, node involvement.
In conclusion:
In early stage NSCCL BMI rarely occurs in the biopsy.lt would thus appear that bone marrow biopsy should not be recommended as a routine pretherapeutic procedere. The SCCL shows the highest BMI rate of all bronchogenic carcinomas. Its presence can be most easily demonstrated in advanced stages. It is extremely rare that BMI is the only proof of a tumor generalization Under these circumstances we cannot recommend the bone marrow biopsy as a routine measure even for early stages of SCCL. Nevertheless, the needle point biopsy on the iliac crest is still the appropriate method to clarify BMI.Biiateral biopsy is recommended.
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